S. 2030: Advancing Targeted Therapies for Rare Diseases Act of 2016


Sep 15, 2015


Reported by Committee on Feb 9, 2016

The committees assigned to this bill sent it to the House or Senate as a whole for consideration on February 9, 2016.


Michael Bennet

Senior Senator from Colorado



Read Text »
Last Updated: Apr 5, 2016
Length: 10 pages


49% chance of being enacted (details)

About the bill

Full Title

A bill to allow the sponsor of an application for the approval of a targeted drug to rely upon data and information with respect to such sponsor's previously approved targeted drugs.

The bill’s titles are written by its sponsor.

Read CRS Summary >


Sep 15, 2015

This is the first step in the legislative process.

Feb 9, 2016
Reported by Committee

A committee has issued a report to the full chamber recommending that the bill be considered further. Only about 1 in 4 bills are reported out of committee.

Passed Senate

Passed House

Signed by the President

This page is about a bill in the United States Congress. A bill must be passed by both the House and Senate in identical form and then be signed by the President to become law.

Links & tools

Primary Source


Congress.gov is updated generally one day after events occur. Legislative activity since the last update may not be reflected on GovTrack. Data via congress project.


Click a format for a citation suggestion: